Loading data for GRFS — first visit, this takes a few seconds.
Grifols S.A. (GRFS)
NasdaqGS: GRFS
· Real-Time Price · USD
8.24
+0.49 (6.32%)
At close: Aug 19, 2026, 8:00 PM
8.25
+0.00%
After-hours: 4:10 PM
Grifols S.A. (GRFS) Stock Price, Analysis & Data
6.32% (1D)
No data available
| Bid | 7.19 |
| Market Cap | 5.61B |
| Revenue (ttm) | 7.42B |
| Net Income (ttm) | 452M |
| Beta | 1.19 |
| EPS (ttm) | 0.76 |
| PE Ratio (ttm) | 10.86 |
| Forward PE | 5.79 |
| P/B (ttm) | 1.76 |
| P/S (ttm) | 0.76 |
| Earnings Date | Feb 25, 2027 |
| Ask | 9.5 |
| Volume | 627,751 |
| Avg. Volume (20D) | 664,359 |
| Open | 7.81 |
| Previous Close | 7.75 |
| Day's Range | 7.81 - 8.38 |
| 52-Week Range | 6.96 - 10.32 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $0.28 (3.63%) |
| Ex-Dividend Date | Jul 2, 2026 |
About GRFS
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurol...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jun 2, 2011
Employees 25,258
Stock Exchange NasdaqGS
Ticker Symbol GRFS
Website https://www.grifols.com
Financial Performance
In 2025, Grifols S.A.'s revenue was 7.52B, an increase of 4.33% compared to the previous year's 7.21B. Earnings were 402M, an increase of 156.05%.
Financial StatementsEarnings Surprise
Grifols S.A. has released their quarterly earnings on Jul 28, 2025:
Grifols S.A. is scheduled to release its earnings on Feb 25, 2027, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2